Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, stands at a critical juncture in its journey to bring novel treatments to ...

HAYWARD, Calif., June 10, 2025--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

HAYWARD, Calif., May 27, 2025--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Last month Arcus reported top -line phase 2 results with the TIGIT drug that it said warranted taking it forward into a phase 3 programme, but so far there's no word from Gilead on a buy-in.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes ...

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Business Central CEO Simon Arcus told Ryan Bridge things will probably still fluctuate in coming years. He says there are often moments where things seem to improve, then sink back again.

Research methods and human development. Doreen Arcus, Ph.D., is interested in the social development of children and youth in the contexts of family, school and community. Her earlier studies of the ...

Insurers already rate Wellington a far higher risk than Auckland, with commercial landlords in the capital facing a stiff excess of 5% of the sum insured. Photo / Mark Mitchell Wellington City ...